Is Novartis stock a buy after the Q4 miss?

We see a selective buy for long-term CHF investors. Fundamentals look sound, the dividend yield is near 3 percent, and balance-sheet metrics are solid. That said, near-term growth looks softer. Consider staggered entries and reassess after the April earnings update for better visibility on margins and pipeline uptake.

What did Novartis say about 2026 guidance?

Management guided to low single-digit sales growth and a slight decline in core EBIT for 2026. The main pressures are patent expiries and US pricing. The company expects newer assets to help offset, but investors should assume slower growth until launches and label expansions ramp through the year.

How serious is the patent cliff for Novartis?

It is a headwind, but manageable if new products scale. Loss of exclusivity and US price pressure can weigh on revenue and margins. Watch uptake in radioligand oncology and immunology assets. Faster adoption could stabilize earnings sooner and support a re-rating of Novartis stock.

When is the next Novartis earnings date?

The next scheduled earnings date is 27 April 2026. That update should refine revenue and core EBIT expectations, provide more detail on pricing dynamics, and highlight progress of key franchises like Cosentyx and Pluvicto. It is a key checkpoint for guidance credibility and capital allocation plans.

Global Market Insights

NOVN.SW Stock Today: February 05 — Q4 Sales Miss, Weak 2026 Outlook

ByHuzaifa Zahoor February 5, 2026

Novartis stock is in focus today after Q4 sales missed expectations and management set a cautious 2026 outlook. The Basel group posted FY2025 profit of $17.4 billion, yet guided to low single-digit sales growth with a slight core EBIT decline next year, citing patent expiries and US pricing pressure. On the SIX, NOVN.SW slipped as investors weighed slowing momentum against strength in Cosentyx and Pluvicto. We explain the drivers, risks, valuation in CHF, and near-term catalysts for Swiss portfolios.